Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 15/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.38 |
| ▸ | RXRA | P19793 | 14/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2583096 | 0.83 | NOTUM (0.56) | NOTUMSTSGRIN1GRIN2BRXRA | |
| SCHEMBL2577567 | 0.82 | KDM4E (0.51) | NOTUMGRIN1GRIN2BRXRA | |
| SCHEMBL12156459 | 0.74 | P2RX7 (0.50) | NOTUMGRIN1GRIN2BRXRA | |
| SCHEMBL25043786 | 0.73 | RXRA (0.38) | NOTUMGRIN1GRIN2BRXRA | |
| SCHEMBL15542645 | 0.73 | FLT3 (0.47) | NOTUMGRIN1GRIN2BRXRA | |
| SCHEMBL2582033 | 0.71 | CA1 (0.39) | NOTUMGRIN1GRIN2BRXRA | |
| SCHEMBL2577899 | 0.71 | NOTUM (0.51) | NOTUMGRIN1GRIN2BRXRA | |
| SCHEMBL16983100 | 0.71 | RXRA (0.42) | NOTUMGRIN1GRIN2BRXRA | |
| SCHEMBL30702184 | 0.71 | NOTUM (0.40) | NOTUM | |
| SCHEMBL2579741 | 0.68 | RXRA (0.47) | NOTUMGRIN1GRIN2BRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796316-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2014-08-05 | — | — | US | claimed |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ (BR) | 2013-10-17 | — | — | US | claimed |
| US-8436027-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2013-05-07 | — | — | US | claimed |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | claimed |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | BOECHAT NUBIA | 2009-02-26 | — | — | US | claimed |
| EP-1976832-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundacao Oswaldo Cruz - Fiocruz (BR) | 2008-10-08 | — | — | EP | claimed |
| WO-2007019660-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundação Oswaldo Cruz - FIOCRUZ (BR) | 2007-02-22 | — | — | WO | claimed |
| US-8796316-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2014-08-05 | — | — | US | disclosed |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ (BR) | 2013-10-17 | — | — | US | disclosed |
| US-8436027-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2013-05-07 | — | — | US | disclosed |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | disclosed |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | BOECHAT NUBIA | 2009-02-26 | — | — | US | disclosed |
| EP-1976832-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundacao Oswaldo Cruz - Fiocruz (BR) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007019660-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundação Oswaldo Cruz - FIOCRUZ (BR) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CYP51A1, IPO5, TBC1D5 | NOTUM 1619/4885STS 484/4885GRIN1 4595/4885 |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | NOTUM 1774/4885STS 696/4885GRIN1 3164/4885 |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | NOTUM 1936/4885STS 741/4885GRIN1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.